This report highlights different factors and opportunities prevailing in the “Global Checkpoint Inhibitor Refractory Cancer Market (2024 Edition)”. According to the report, the Global Checkpoint Inhibitor Refractory Cancer Market was valued at USD 34.26 billion in 2023 and is expected to grow at a CAGR of 11.7% during 2025-2030.
The report explores a multi-faceted opportunity landscape in terms of market segmentation by Application (Melanoma, Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Kidney Cancer and Other Applications), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Other End-Users) and By Inhibitor Type (PD-L1 Inhibitors and PD-1 Inhibitors)
One of the primary drivers of the Checkpoint Inhibitor Refractory Cancer market is the increasing incidence of cancers resistant to checkpoint inhibitors. Despite the success of these therapies in treating various cancers, a subset of patients does not respond or eventually develops resistance. This challenge has led to significant research efforts focused on understanding the mechanisms of resistance and developing new treatment strategies.
The growing focus on immunotherapy and combination therapies has also played a crucial role in the market's growth. Researchers and pharmaceutical companies are exploring various approaches to enhance the efficacy of checkpoint inhibitors, including combining them with other immunotherapies, targeted therapies, or traditional treatments like chemotherapy. These combination strategies aim to overcome resistance and improve patient outcomes.
The increasing focus on personalized medicine, including biomarker testing, has influenced the market. This approach helps in identifying the most effective treatments for individual patients, based on the specific characteristics of their cancer.
In the Americas, the market benefits from strong support for cancer research, the presence of leading pharmaceutical companies, and a well-established regulatory framework. The growing awareness of personalized medicine and the availability of advanced diagnostic tools also contribute to market growth.
The Asia Pacific region is expected to witness the highest growth rate, driven by increasing healthcare investments, rising cancer incidence, and expanding access to advanced treatments. Countries like China, Japan, and India are key markets, with a growing focus on improving cancer care and research.
In Europe, the market for Checkpoint Inhibitor Refractory Cancer treatments is driven by a well-established healthcare system, high patient awareness, and ongoing research efforts. Countries like Germany, France, and the UK are significant contributors, with a focus on developing new therapies and improving patient outcomes.
This product will be delivered within 2 business days.
The report explores a multi-faceted opportunity landscape in terms of market segmentation by Application (Melanoma, Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Kidney Cancer and Other Applications), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Other End-Users) and By Inhibitor Type (PD-L1 Inhibitors and PD-1 Inhibitors)
Market Overview
The Checkpoint Inhibitor Refractory Cancer market has experienced significant growth due to the increasing prevalence of cancers that do not respond to checkpoint inhibitors, advancements in immunotherapy, and rising awareness of personalized cancer treatments. Checkpoint inhibitors are a class of drugs that block proteins on immune cells, enabling them to attack cancer cells. However, some cancers develop resistance to these therapies, necessitating alternative treatments. The market is driven by the need for effective therapies to manage and treat refractory cancers.One of the primary drivers of the Checkpoint Inhibitor Refractory Cancer market is the increasing incidence of cancers resistant to checkpoint inhibitors. Despite the success of these therapies in treating various cancers, a subset of patients does not respond or eventually develops resistance. This challenge has led to significant research efforts focused on understanding the mechanisms of resistance and developing new treatment strategies.
The growing focus on immunotherapy and combination therapies has also played a crucial role in the market's growth. Researchers and pharmaceutical companies are exploring various approaches to enhance the efficacy of checkpoint inhibitors, including combining them with other immunotherapies, targeted therapies, or traditional treatments like chemotherapy. These combination strategies aim to overcome resistance and improve patient outcomes.
The increasing focus on personalized medicine, including biomarker testing, has influenced the market. This approach helps in identifying the most effective treatments for individual patients, based on the specific characteristics of their cancer.
Geographical Insights
Americas represent the largest market for Checkpoint Inhibitor Refractory Cancer treatments, driven by a strong healthcare infrastructure, significant research activities, and a high prevalence of cancer. The United States is a key market, with a focus on developing innovative therapies and improving patient care.In the Americas, the market benefits from strong support for cancer research, the presence of leading pharmaceutical companies, and a well-established regulatory framework. The growing awareness of personalized medicine and the availability of advanced diagnostic tools also contribute to market growth.
The Asia Pacific region is expected to witness the highest growth rate, driven by increasing healthcare investments, rising cancer incidence, and expanding access to advanced treatments. Countries like China, Japan, and India are key markets, with a growing focus on improving cancer care and research.
In Europe, the market for Checkpoint Inhibitor Refractory Cancer treatments is driven by a well-established healthcare system, high patient awareness, and ongoing research efforts. Countries like Germany, France, and the UK are significant contributors, with a focus on developing new therapies and improving patient outcomes.
Market Segmentation
By Application:
- Melanoma
- Hodgkin Lymphoma
- Non-Small Cell Lung Cancer
- Kidney Cancer
- Other Applications
By End-User:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Other End-Users
By Inhibitor Type:
- PD-L1 Inhibitors
- PD-1 Inhibitors
By Geography:
- Americas (The United States, Canada, Brazil, Mexico, Rest of Americas)
- Europe (United Kingdom, Germany, France, Italy, Spain, Turkey, Russia, Rest of Europe)
- Asia Pacific (China, Japan, South Korea, India, Singapore, Indonesia, Rest of Asia Pacific)
- Middle East and Africa (GCC, Israel, South Africa, Rest of Middle East and Africa)
Key Companies
The report assesses the competitive developments, strategies, mergers and acquisitions and new product development and market share portfolio of top 15 companies. Key companies in the Global Checkpoint Inhibitor Refractory Cancer Market include:- Janssen Research and Development, LLC
- 4D pharma plc.
- 4SC AG
- Exicure, Inc.
- ImmunityBio
- Merck
- Regeneron Pharmaceuticals
- Merck KGaA and Pfizer
- Bristol-Myers Squibb
- AstraZeneca
- Genentech/Hoffmann-La Roche
- Other Leading Companies
Reasons to buy this report:
- In-Depth Comparative Assessment of Top 20 Markets in the Checkpoint Inhibitor Refractory Cancer Market: Comparative assessment of 20 leading countries highlighting the total addressable market, opportunities, lucrative segments and competitive positioning of leading companies.
- Comprehensive Historical, Present, and Future Analytics of the Checkpoint Inhibitor Refractory Cancer Market: A deep dive in the historical (2020-2023), current (2024) and forecast (2025-2030) market analytics of Checkpoint Inhibitor Refractory Cancer Market.
- Detailed Analysis of Checkpoint Inhibitor Refractory Cancer Market By Application, End-User, and Inhibitor Type Across 20 Countries
- Beyond the Purchase: 90 Days of Support
- Direct Access to Analysts: Have questions after reading the report? Our expert analysts are just a call or email away.
- Customized Assistance: Whether you're integrating insights into your strategy or have questions about market dynamics, our team provides tailored support to meet your specific business needs.
- Data Customization Requests: During the support period, you have the flexibility to request additional data cuts or deeper dives into specific areas of interest.
- Gain insights specific to new entrants or new market areas to tap: The study provides detailed market entry strategies, including analysis of barriers to entry, pricing strategies, opportunities, trends, drivers, and challenges and product positioning using the Opportunity Portfolio Matrix (OPM)
- Strategic Company Movements: Tracking Competitive Developments and Key Players in the Market: The report covers competitive strategies, mergers & acquisitions, new developments, future plans and market share analysis of ~15 top companies.
This product will be delivered within 2 business days.
Table of Contents
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
1.2 Executive Summary
1.3 Research Methodology
3. Global Checkpoint Inhibitor Refractory Cancer Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Global Checkpoint Inhibitor Refractory Cancer Market
3.2 Checkpoint Inhibitor Refractory Cancer Market Type Matrix
3.3 Global Checkpoint Inhibitor Refractory Cancer Market: Dashboard
3.4 Global Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
3.5 Global Checkpoint Inhibitor Refractory Cancer Market: Market Value Assessment
3.6 Assessment Degree of Impact of COVID-19 on Global Checkpoint Inhibitor Refractory Cancer Market
3.7 Global Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
3.7.1 Global Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
3.7.2 Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Index, By Application (2025-2030)
3.7.3 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
3.7.4 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
3.7.5 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.7.6 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.7.7 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
3.8 Global Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
3.8.1 Global Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
3.8.2 Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Index, By End-User (2025-2030)
3.8.3 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
3.8.4 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
3.8.5 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
3.8.6 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
3.9 Global Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
3.9.1 Global Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
3.9.2 Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Index, By Inhibitor Type (2025-2030)
3.9.3 Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
3.9.4 Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
3.2 Checkpoint Inhibitor Refractory Cancer Market Type Matrix
3.3 Global Checkpoint Inhibitor Refractory Cancer Market: Dashboard
3.4 Global Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
3.5 Global Checkpoint Inhibitor Refractory Cancer Market: Market Value Assessment
3.6 Assessment Degree of Impact of COVID-19 on Global Checkpoint Inhibitor Refractory Cancer Market
3.7 Global Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
3.7.1 Global Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
3.7.2 Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Index, By Application (2025-2030)
3.7.3 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
3.7.4 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
3.7.5 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.7.6 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
3.7.7 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
3.8 Global Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
3.8.1 Global Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
3.8.2 Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Index, By End-User (2025-2030)
3.8.3 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
3.8.4 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
3.8.5 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
3.8.6 Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
3.9 Global Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
3.9.1 Global Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
3.9.2 Global Checkpoint Inhibitor Refractory Cancer Market Attractiveness Index, By Inhibitor Type (2025-2030)
3.9.3 Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
3.9.4 Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
4. Checkpoint Inhibitor Refractory Cancer Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
4.2 Regional Snapshot
5. Americas Checkpoint Inhibitor Refractory Cancer Market: Historic and Forecast
5.1 Americas Checkpoint Inhibitor Refractory Cancer Market: Snapshot
5.2 Americas Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
5.3 Americas Checkpoint Inhibitor Refractory Cancer Market: Key Factors
5.4 Americas Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
5.5 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
5.5.1 Americas Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
5.5.2 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
5.5.3 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
5.5.4 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.5.5 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.5.6 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
5.6 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
5.6.1 Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
5.6.2 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
5.6.3 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
5.6.4 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
5.6.5 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
5.7 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
5.7.1 Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
5.7.2 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
5.7.3 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
5.8 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
5.8.1 Americas Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
5.8.2 United States Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.2.1 United States Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.2.2 United States Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.2.3 United States Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.3 Canada Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.3.1 Canada Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.3.2 Canada Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.3.3 Canada Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.4 Brazil Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.4.1 Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.4.2 Brazil Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.4.3 Brazil Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.5 Mexico Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.5.1 Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.5.2 Mexico Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.5.3 Mexico Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.6 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.6.1 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.6.2 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.6.3 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.2 Americas Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
5.3 Americas Checkpoint Inhibitor Refractory Cancer Market: Key Factors
5.4 Americas Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
5.5 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
5.5.1 Americas Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
5.5.2 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
5.5.3 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
5.5.4 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.5.5 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
5.5.6 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
5.6 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
5.6.1 Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
5.6.2 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
5.6.3 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
5.6.4 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
5.6.5 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
5.7 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
5.7.1 Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
5.7.2 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
5.7.3 Americas Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
5.8 Americas Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
5.8.1 Americas Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
5.8.2 United States Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.2.1 United States Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.2.2 United States Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.2.3 United States Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.3 Canada Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.3.1 Canada Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.3.2 Canada Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.3.3 Canada Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.4 Brazil Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.4.1 Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.4.2 Brazil Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.4.3 Brazil Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.5 Mexico Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.5.1 Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.5.2 Mexico Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.5.3 Mexico Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
5.8.6 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
5.8.6.1 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Application
5.8.6.2 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User
5.8.6.3 Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6. Europe Checkpoint Inhibitor Refractory Cancer Market: Historic and Forecast
6.1 Europe Checkpoint Inhibitor Refractory Cancer Market: Snapshot
6.2 Europe Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, BY Value, 2020-2030 (USD Million & CAGR)
6.3 Europe Checkpoint Inhibitor Refractory Cancer Market: Key Factors
6.4 Europe Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
6.5 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
6.5.1 Europe Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
6.5.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
6.5.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
6.5.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.5.5 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.5.6 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
6.6 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
6.6.1 Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
6.6.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
6.6.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
6.6.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
6.6.5 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
6.7 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
6.7.1 Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
6.7.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
6.7.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
6.8 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
6.8.1 Europe Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
6.8.2 Russia Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.2.1 Russia Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.2.2 Russia Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.2.3 Russia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.3 France Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.3.1 France Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.3.2 France Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.3.3 France Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.4 United Kingdom Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.4.1 United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.4.2 United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.4.3 United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.5 Germany Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.5.1 Germany Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.5.2 Germany Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.5.3 Germany Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.6 Italy Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.6.1 Italy Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.6.2 Italy Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.6.3 Italy Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.7 Spain Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.7.1 Spain Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.7.2 Spain Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.7.3 Spain Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.8 Turkey Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.8.1 Turkey Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.8.2 Turkey Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.8.3 Turkey Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.9 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.9.1 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.9.2 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.9.3 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.2 Europe Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, BY Value, 2020-2030 (USD Million & CAGR)
6.3 Europe Checkpoint Inhibitor Refractory Cancer Market: Key Factors
6.4 Europe Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
6.5 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
6.5.1 Europe Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
6.5.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
6.5.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
6.5.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.5.5 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
6.5.6 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
6.6 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
6.6.1 Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
6.6.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
6.6.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
6.6.4 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
6.6.5 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
6.7 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
6.7.1 Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
6.7.2 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
6.7.3 Europe Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
6.8 Europe Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
6.8.1 Europe Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
6.8.2 Russia Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.2.1 Russia Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.2.2 Russia Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.2.3 Russia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.3 France Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.3.1 France Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.3.2 France Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.3.3 France Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.4 United Kingdom Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.4.1 United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.4.2 United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.4.3 United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.5 Germany Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.5.1 Germany Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.5.2 Germany Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.5.3 Germany Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.6 Italy Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.6.1 Italy Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.6.2 Italy Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.6.3 Italy Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.7 Spain Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.7.1 Spain Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.7.2 Spain Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.7.3 Spain Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.8 Turkey Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.8.1 Turkey Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.8.2 Turkey Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.8.3 Turkey Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
6.8.9 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
6.8.9.1 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application
6.8.9.2 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User
6.8.9.3 Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7. Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Historic and Forecast
7.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Snapshot
7.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
7.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Key Factors
7.4 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
7.5 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
7.5.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
7.5.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
7.5.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
7.5.4 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.5.5 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.5.6 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
7.6 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
7.6.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
7.6.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
7.6.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
7.6.4 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
7.6.5 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
7.7 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
7.7.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
7.7.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
7.7.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
7.8 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
7.8.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
7.8.2 China Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.2.1 China Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.2.2 China Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.2.3 China Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.3 India Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.3.1 India Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.3.2 India Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.3.3 India Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.4 South Korea Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.4.1 South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.4.2 South Korea Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.4.3 South Korea Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.5 Japan Korea Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.5.1 Japan Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.5.2 Japan Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.5.3 Japan Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.6 Singapore Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.6.1 Singapore Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.6.2 Singapore Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.6.3 Singapore Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.7 Indonesia Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.7.1 Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.7.2 Indonesia Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.7.3 Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.8 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.8.1 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.8.2 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.8.3 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
7.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Key Factors
7.4 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
7.5 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
7.5.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
7.5.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
7.5.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
7.5.4 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.5.5 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
7.5.6 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
7.6 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
7.6.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
7.6.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
7.6.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
7.6.4 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
7.6.5 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
7.7 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
7.7.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
7.7.2 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
7.7.3 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
7.8 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
7.8.1 Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
7.8.2 China Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.2.1 China Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.2.2 China Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.2.3 China Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.3 India Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.3.1 India Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.3.2 India Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.3.3 India Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.4 South Korea Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.4.1 South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.4.2 South Korea Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.4.3 South Korea Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.5 Japan Korea Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.5.1 Japan Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.5.2 Japan Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.5.3 Japan Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.6 Singapore Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.6.1 Singapore Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.6.2 Singapore Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.6.3 Singapore Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.7 Indonesia Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.7.1 Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.7.2 Indonesia Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.7.3 Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
7.8.8 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
7.8.8.1 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application
7.8.8.2 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User
7.8.8.3 Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8. Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market: Historic and Forecast
8.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market: Snapshot
8.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
8.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market: Key Factors
8.4 Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
8.5 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
8.5.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
8.5.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
8.5.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
8.5.4 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.5.5 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.5.6 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
8.6 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
8.6.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
8.6.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
8.6.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
8.6.4 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
8.6.5 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
8.7 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
8.7.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
8.7.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
8.7.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
8.8 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
8.8.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
8.8.2 GCC Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.2.1 GCC Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.2.2 GCC Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.2.3 GCC Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8.8.3 Israel Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.3.1 Israel Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.3.2 Israel Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.3.3 Israel Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8.8.4 South Africa Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.4.1 South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.4.2 South Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.4.3 South Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8.8.5 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.5.1 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.5.2 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.5.3 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, By Value, 2020-2030 (USD Million & CAGR)
8.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market: Key Factors
8.4 Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market: Segment Analysis
8.5 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Application
8.5.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, By Application Overview
8.5.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
8.5.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
8.5.4 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.5.5 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
8.5.6 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
8.6 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By End-User
8.6.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User Overview
8.6.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
8.6.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
8.6.4 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
8.6.5 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
8.7 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Inhibitor Type
8.7.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type Overview
8.7.2 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
8.7.3 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
8.8 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market Segmentation: By Country
8.8.1 Middle East & Africa Checkpoint Inhibitor Refractory Cancer Market, by Country Overview
8.8.2 GCC Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.2.1 GCC Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.2.2 GCC Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.2.3 GCC Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8.8.3 Israel Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.3.1 Israel Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.3.2 Israel Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.3.3 Israel Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8.8.4 South Africa Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.4.1 South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.4.2 South Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.4.3 South Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
8.8.5 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
8.8.5.1 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application
8.8.5.2 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User
8.8.5.3 Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Checkpoint Inhibitor Refractory Cancer Market
9.2 Drivers
9.3 Restraints
9.4 Trends
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Ecosystem Analysis
10.1 Porter Analysis
11. Competitive Positioning
11.1 Companies’ Competitive Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Checkpoint Inhibitor Refractory Cancer Market
11.4 Company Profiles
11.4.1 Janssen Research and Development, LLC
11.4.2 4D pharma plc.
11.4.3 4SC AG
11.4.4 Exicure, Inc.
11.4.5 ImmunityBio
11.4.6 Merck
11.4.7 Regeneron Pharmaceuticals
11.4.8 Merck KGaA and Pfizer
11.4.9 Bristol-Myers Squibb
11.4.10 AstraZeneca
11.4.11 Genentech/Hoffmann-La Roche
11.4.12 Other Leading Companies
11.2 Market Position Matrix
11.3 Market Share Analysis of Checkpoint Inhibitor Refractory Cancer Market
11.4 Company Profiles
11.4.1 Janssen Research and Development, LLC
11.4.2 4D pharma plc.
11.4.3 4SC AG
11.4.4 Exicure, Inc.
11.4.5 ImmunityBio
11.4.6 Merck
11.4.7 Regeneron Pharmaceuticals
11.4.8 Merck KGaA and Pfizer
11.4.9 Bristol-Myers Squibb
11.4.10 AstraZeneca
11.4.11 Genentech/Hoffmann-La Roche
11.4.12 Other Leading Companies
List of Figures
Figure 1: Checkpoint Inhibitor Refractory Cancer Market, Comparison of Leading Countries, 2023 (%)
Figure 2: Checkpoint Inhibitor Refractory Cancer Market, Comparison of Leading Countries, 2030 (%)
Figure 3: Checkpoint Inhibitor Refractory Cancer Market Type Matrix
Figure 4: Checkpoint Inhibitor Refractory Cancer Market Demand Analysis
Figure 5: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020-2023 (USD Million)
Figure 6: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2024-2030 (USD Million)
Figure 7: Global Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 8: Global Checkpoint Inhibitor Refractory Cancer Market CAGR, 2020-2023 (%)
Figure 9: Global Checkpoint Inhibitor Refractory Cancer Market CAGR, 2025-2030 (%)
Figure 10: Global Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 11: Market Attractiveness Analysis of Global Checkpoint Inhibitor Refractory Cancer Market, By Application (2025-2030)
Figure 12: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
Figure 13: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Melanoma, 2020-2030 (USD Million)
Figure 14: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
Figure 15: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Hodgkin Lymphoma, 2020-2030 (USD Million)
Figure 16: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
Figure 17: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Non-Small Cell Lung Cancer, 2020-2030 (USD Million)
Figure 18: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
Figure 19: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Kidney Cancer, 2020-2030 (USD Million)
Figure 20: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
Figure 21: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Other Applications, 2020-2030 (USD Million)
Figure 22: Market Attractiveness Analysis of Global Checkpoint Inhibitor Refractory Cancer Market, By End-User (2025-2030)
Figure 23: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
Figure 24: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Hospitals, 2020-2030 (USD Million)
Figure 25: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
Figure 26: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Specialty Clinics, 2020-2030 (USD Million)
Figure 27: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
Figure 28: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Ambulatory Surgical Centers, 2020-2030 (USD Million)
Figure 29: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
Figure 30: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Other End-Users, 2020-2030 (USD Million)
Figure 31: Market Attractiveness Analysis of Global Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type (2025-2030)
Figure 32: Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
Figure 33: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By PD-L1 Inhibitors, 2020-2030 (USD Million)
Figure 34: Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
Figure 35: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By PD-1 Inhibitors, 2020-2030 (USD Million)
Figure 36: Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 37: Americas Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 38: Americas Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 39: Americas Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 40: Americas Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 41: Americas Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 42: Americas Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 43: Americas Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 44: Americas Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 45: Americas Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 46: Figure 46: Americas Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 47: Americas Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 48: Americas Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 49: Americas Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 50: Americas Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 51: Americas Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 52: United States Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 53: United States Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 54: United States Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 55: United States Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 56: United States Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 57: Canada Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 58: Canada Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 59: Canada Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 60: Canada Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 61: Canada Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 62: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 63: Brazil Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 64: Brazil Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 65: Brazil Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 66: Brazil Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 67: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 68: Mexico Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 69: Mexico Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 70: Mexico Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 71: Mexico Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 72: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 73: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 74: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 75: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 76: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 77: Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 78: Europe Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 79: Europe Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 80: Europe Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 81: Europe Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 82: Europe Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 83: Europe Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 84: Europe Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 85: Europe Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 86: Europe Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 87: Europe Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 88: Europe Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 89: Europe Checkpoint Inhibitor Refractory Cancer Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 90: Europe Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 91: Europe Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 92: Europe Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 93: Russia Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 94: Russia Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 95: Russia Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 96: Russia Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 97: Russia Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 98: France Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 99: France Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 100: France Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 101: France Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 102: France Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 103: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 104: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 105: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 106: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 107: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 108: Germany Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 109: Germany Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 110: Germany Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 111: Germany Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 112: Germany Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 113: Italy Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 114: Italy Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 115: Italy Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 116: Italy Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 117: Italy Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 118: Spain Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 119: Spain Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 120: Spain Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 121: Spain Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 122: Spain Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 123: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 124: Turkey Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 125: Turkey Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 126: Turkey Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 127: Turkey Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 128: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 129: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 130: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 131: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 132: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 133: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 134: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 135: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 136: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 137: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 138: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 139: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 140: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 141: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 142: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 143: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 144: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 145: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 146: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 147: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 148: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 149: China Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 150: China Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 151: China Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 152: China Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 153: China Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 154: India Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 155: India Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 156: India Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 157: India Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 158: India Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 159: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 160: South Korea Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 161: South Korea Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 162: South Korea Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 163: South Korea Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 164: Japan Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 165: Japan Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 166: Japan Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 167: Japan Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 168: Japan Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 169: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 170: Singapore Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 171: Singapore Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 172: Singapore Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 173: Singapore Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 174: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 175: Indonesia Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 176: Indonesia Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 177: Indonesia Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 178: Indonesia Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 179: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 180: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 181: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 182: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 183: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 184: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 185: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 186: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 187: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 188: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 189: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 190: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 191: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 192: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 193: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 194: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 195: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 196: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 197: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 198: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 199: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 200: GCC Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 201: GCC Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 202: GCC Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 203: GCC Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 204: GCC Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 205: Israel Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 206: Israel Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 207: Israel Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 208: Israel Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 209: Israel Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 210: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 211: South Africa Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 212: South Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 213: South Africa Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 214: South Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 215: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 216: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 217: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 218: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 219: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 220: Market Share of Prominent Companies of Global Checkpoint Inhibitor Refractory Cancer Market, 2023 (%)
Figure 2: Checkpoint Inhibitor Refractory Cancer Market, Comparison of Leading Countries, 2030 (%)
Figure 3: Checkpoint Inhibitor Refractory Cancer Market Type Matrix
Figure 4: Checkpoint Inhibitor Refractory Cancer Market Demand Analysis
Figure 5: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020-2023 (USD Million)
Figure 6: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2024-2030 (USD Million)
Figure 7: Global Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 8: Global Checkpoint Inhibitor Refractory Cancer Market CAGR, 2020-2023 (%)
Figure 9: Global Checkpoint Inhibitor Refractory Cancer Market CAGR, 2025-2030 (%)
Figure 10: Global Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 11: Market Attractiveness Analysis of Global Checkpoint Inhibitor Refractory Cancer Market, By Application (2025-2030)
Figure 12: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Melanoma, By Value, 2020H-2030F (USD Million & CAGR)
Figure 13: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Melanoma, 2020-2030 (USD Million)
Figure 14: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Million & CAGR)
Figure 15: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Hodgkin Lymphoma, 2020-2030 (USD Million)
Figure 16: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Million & CAGR)
Figure 17: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Non-Small Cell Lung Cancer, 2020-2030 (USD Million)
Figure 18: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Kidney Cancer, By Value, 2020H-2030F (USD Million & CAGR)
Figure 19: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Kidney Cancer, 2020-2030 (USD Million)
Figure 20: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other Applications, By Value, 2020H-2030F (USD Million & CAGR)
Figure 21: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Other Applications, 2020-2030 (USD Million)
Figure 22: Market Attractiveness Analysis of Global Checkpoint Inhibitor Refractory Cancer Market, By End-User (2025-2030)
Figure 23: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR)
Figure 24: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Hospitals, 2020-2030 (USD Million)
Figure 25: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Specialty Clinics, By Value, 2020H-2030F (USD Million & CAGR)
Figure 26: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Specialty Clinics, 2020-2030 (USD Million)
Figure 27: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR)
Figure 28: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Ambulatory Surgical Centers, 2020-2030 (USD Million)
Figure 29: Global Checkpoint Inhibitor Refractory Cancer Market Size, By Other End-Users, By Value, 2020H-2030F (USD Million & CAGR)
Figure 30: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By Other End-Users, 2020-2030 (USD Million)
Figure 31: Market Attractiveness Analysis of Global Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type (2025-2030)
Figure 32: Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
Figure 33: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By PD-L1 Inhibitors, 2020-2030 (USD Million)
Figure 34: Global Checkpoint Inhibitor Refractory Cancer Market Size, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Million & CAGR)
Figure 35: Global Checkpoint Inhibitor Refractory Cancer Market Absolute Opportunity, By PD-1 Inhibitors, 2020-2030 (USD Million)
Figure 36: Americas Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 37: Americas Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 38: Americas Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 39: Americas Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 40: Americas Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 41: Americas Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 42: Americas Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 43: Americas Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 44: Americas Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 45: Americas Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 46: Figure 46: Americas Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 47: Americas Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 48: Americas Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 49: Americas Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 50: Americas Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 51: Americas Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 52: United States Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 53: United States Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 54: United States Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 55: United States Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 56: United States Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 57: Canada Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 58: Canada Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 59: Canada Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 60: Canada Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 61: Canada Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 62: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 63: Brazil Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 64: Brazil Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 65: Brazil Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 66: Brazil Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 67: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 68: Mexico Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 69: Mexico Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 70: Mexico Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 71: Mexico Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 72: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 73: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 74: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 75: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 76: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 77: Europe Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 78: Europe Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 79: Europe Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 80: Europe Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 81: Europe Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 82: Europe Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 83: Europe Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 84: Europe Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 85: Europe Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 86: Europe Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 87: Europe Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 88: Europe Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 89: Europe Checkpoint Inhibitor Refractory Cancer Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 90: Europe Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 91: Europe Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 92: Europe Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 93: Russia Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 94: Russia Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 95: Russia Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 96: Russia Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 97: Russia Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 98: France Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 99: France Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 100: France Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 101: France Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 102: France Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 103: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 104: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 105: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 106: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 107: United Kingdom Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 108: Germany Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 109: Germany Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 110: Germany Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 111: Germany Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 112: Germany Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 113: Italy Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 114: Italy Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 115: Italy Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 116: Italy Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 117: Italy Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 118: Spain Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 119: Spain Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 120: Spain Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 121: Spain Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 122: Spain Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 123: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 124: Turkey Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 125: Turkey Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 126: Turkey Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 127: Turkey Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 128: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 129: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 130: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 131: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 132: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 133: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 134: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 135: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 136: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 137: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 138: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 139: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 140: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 141: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 142: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 143: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 144: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 145: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 146: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 147: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 148: Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 149: China Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 150: China Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 151: China Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 152: China Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 153: China Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 154: India Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 155: India Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 156: India Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 157: India Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 158: India Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 159: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 160: South Korea Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 161: South Korea Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 162: South Korea Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 163: South Korea Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 164: Japan Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 165: Japan Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 166: Japan Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 167: Japan Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 168: Japan Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 169: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 170: Singapore Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 171: Singapore Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 172: Singapore Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 173: Singapore Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 174: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 175: Indonesia Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 176: Indonesia Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 177: Indonesia Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 178: Indonesia Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 179: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 180: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 181: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 182: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 183: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 184: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Size, By Value, 2020H-2030F (USD Million)
Figure 185: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, 2023 (%)
Figure 186: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By New Product Launches, 2023 (%)
Figure 187: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Company, 2023 (%)
Figure 188: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market CAGR (%), By Region, 2020-2023, 2025-2030
Figure 189: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Melanoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 190: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Hodgkin Lymphoma, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 191: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Non-Small Cell Lung Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 192: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Kidney Cancer, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 193: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Other Applications, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 194: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Hospitals, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 195: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Specialty Clinics, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 196: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 197: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Other End-Users, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 198: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By PD-L1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 199: Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By PD-1 Inhibitors, By Value, 2020H-2030F (USD Millions & CAGR)
Figure 200: GCC Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 201: GCC Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 202: GCC Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 203: GCC Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 204: GCC Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 205: Israel Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 206: Israel Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 207: Israel Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 208: Israel Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 209: Israel Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 210: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 211: South Africa Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 212: South Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 213: South Africa Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 214: South Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 215: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Value, 2020-2030 (USD Million & CAGR)
Figure 216: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Value, By Inhibitor Type, 2023 (USD Million)
Figure 217: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Application, By Value, 2023 (%)
Figure 218: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By End-User, By Value, 2023 (%)
Figure 219: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market Share, By Inhibitor Type, By Value, 2023 (%)
Figure 220: Market Share of Prominent Companies of Global Checkpoint Inhibitor Refractory Cancer Market, 2023 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: United States Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A3: United States Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A4: United States Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A5: United States Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A6: United States Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A7: United States Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A8: Canada Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A9: Canada Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024- 2030 (USD Million)
Table A10: Canada Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A11: Canada Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A12: Canada Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A13: Canada Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A14: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A15: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A16: Brazil Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A17: Brazil Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A18: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A19: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A20: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A21: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A22: Mexico Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A23: Mexico Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A24: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A25: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A26: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A27: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A28: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A29: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A30: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A31: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A32: Russia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A33: Russia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A34: Russia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A35: Russia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A36: Russia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A37: Russia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A38: France Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A39: France Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A40: France Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A41: France Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A42: France Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A43: France Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A44: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A45: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A46: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A47: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A48: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A49: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A50: Germany Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A51: Germany Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A52: Germany Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A53: Germany Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A54: Germany Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A55: Germany Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A56: Italy Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A57: Italy Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A58: Italy Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A59: Italy Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A60: Italy Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A61: Italy Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A62: Spain Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A63: Spain Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A64: Spain Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A65: Spain Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A66: Spain Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A67: Spain Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A68: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A69: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A70: Turkey Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A71: Turkey Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A72: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A73: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A74: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A75: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A76: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A77: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A78: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A79: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A80: China Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A81: China Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A82: China Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A83: China Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A84: China Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A85: China Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A86: India Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A87: India Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A88: India Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A89: India Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A90: India Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A91: India Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A92: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A93: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A94: South Korea Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A95: South Korea Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A96: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A97: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A98: Japan Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A99: Japan Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A100: Japan Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A101: Japan Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A102: Japan Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A103: Japan Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A104: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A105: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A106: Singapore Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A107: Singapore Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A108: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A109: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A110: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A111: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A112: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A113: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A114: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A115: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A116: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A117: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A118: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A119: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A120: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A121: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A122: GCC Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A123: GCC Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A124: GCC Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A125: GCC Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A126: GCC Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A127: GCC Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A128: Israel Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A129: Israel Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A130: Israel Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A131: Israel Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A132: Israel Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A133: Israel Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A134: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A135: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A136: South Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A137: South Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A138: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A139: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A140: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A141: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A142: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A143: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A144: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A145: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A2: United States Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A3: United States Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A4: United States Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A5: United States Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A6: United States Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A7: United States Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A8: Canada Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A9: Canada Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024- 2030 (USD Million)
Table A10: Canada Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A11: Canada Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A12: Canada Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A13: Canada Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A14: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A15: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A16: Brazil Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A17: Brazil Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A18: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A19: Brazil Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A20: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A21: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A22: Mexico Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A23: Mexico Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A24: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A25: Mexico Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A26: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A27: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A28: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A29: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A30: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A31: Rest of Americas Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A32: Russia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A33: Russia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A34: Russia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A35: Russia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A36: Russia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A37: Russia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A38: France Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A39: France Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A40: France Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A41: France Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A42: France Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A43: France Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A44: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A45: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A46: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A47: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A48: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A49: United Kingdom Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A50: Germany Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A51: Germany Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A52: Germany Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A53: Germany Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A54: Germany Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A55: Germany Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A56: Italy Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A57: Italy Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A58: Italy Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A59: Italy Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A60: Italy Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A61: Italy Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A62: Spain Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A63: Spain Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A64: Spain Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A65: Spain Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A66: Spain Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A67: Spain Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A68: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A69: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A70: Turkey Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A71: Turkey Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A72: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A73: Turkey Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A74: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A75: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A76: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A77: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A78: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A79: Rest of Europe Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A80: China Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A81: China Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A82: China Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A83: China Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A84: China Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A85: China Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A86: India Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A87: India Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A88: India Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A89: India Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A90: India Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A91: India Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A92: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A93: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A94: South Korea Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A95: South Korea Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A96: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A97: South Korea Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A98: Japan Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A99: Japan Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A100: Japan Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A101: Japan Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A102: Japan Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A103: Japan Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A104: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A105: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A106: Singapore Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A107: Singapore Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A108: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A109: Singapore Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A110: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A111: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A112: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A113: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A114: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A115: Indonesia Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A116: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A117: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A118: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A119: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A120: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A121: Rest of Asia Pacific Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A122: GCC Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A123: GCC Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A124: GCC Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A125: GCC Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A126: GCC Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A127: GCC Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A128: Israel Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A129: Israel Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A130: Israel Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A131: Israel Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A132: Israel Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A133: Israel Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A134: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A135: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A136: South Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A137: South Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A138: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A139: South Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Table A140: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2020-2023 (USD Million)
Table A141: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Application, By Value, 2024-2030 (USD Million)
Table A142: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2020-2023 (USD Million)
Table A143: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By End-User, By Value, 2024-2030 (USD Million)
Table A144: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2020-2023 (USD Million)
Table A145: Rest of Middle East and Africa Checkpoint Inhibitor Refractory Cancer Market, By Inhibitor Type, By Value, 2024-2030 (USD Million)
Companies Mentioned
- Janssen Research and Development, LLC
- 4D pharma plc.
- 4SC AG
- Exicure, Inc.
- ImmunityBio
- Merck
- Regeneron Pharmaceuticals
- Merck KGaA and Pfizer
- Bristol-Myers Squibb
- AstraZeneca
- Genentech/Hoffmann-La Roche
